A Study of Ritonavir (an Anti-HIV Drug) in HIV-Positive Infants and Children
Status:
Completed
Trial end date:
2004-01-01
Target enrollment:
Participant gender:
Summary
The study examines the safety and effectiveness of ritonavir (an anti-HIV drug), alone and in
combination with other anti-HIV drugs, in HIV-positive children under 2 years of age. This
study will also determine the most effective doses of ritonavir for future pediatric HIV
studies.
Infants infected with HIV by their mothers experience faster disease progression than adults
or older children. Treatment with anti-HIV drugs administered at an early age may slow
disease progression in infant populations.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)